Written by Johnathon Anderson, Ph.D., a research scientist, and Associate Professor at the University of California Davis School of Medicine
Published by: Peptide Systems
Key Takeaways
The "Amplifier + Trigger" Synergy: Research indicates that co-administering CJC-1295 (a GHRH analog) and Ipamorelin (a selective secretagogue) creates a supra-additive effect. By simultaneously increasing cAMP (the fuel) and intracellular Calcium (the spark), the combination generates a Growth Hormone pulse significantly larger than the sum of individual administrations.
Selective "Clean" Signaling: Unlike first-generation secretagogues (GHRP-6), Ipamorelin is distinguished by its high selectivity. Studies (Raun et al., 1998) confirm it triggers the somatotropic axis without elevating Cortisol (stress) or Prolactin, allowing for a purely anabolic signaling environment.
The "No DAC" Advantage: To maintain insulin sensitivity and avoid "GH bleed," modern protocols favor Modified GRF 1-29 (CJC-1295 No DAC). Its short 30-minute half-life mimics the body’s natural pulsatile rhythm, whereas the "DAC" version (8-day half-life) creates continuous, unnatural elevation.
Dual-Effector Mechanisms: This approach leverages the dual pathways of Growth Hormone physiology: Direct Effects (Lipolysis/Fat Loss) via the JAK2-STAT5 pathway on adipocytes, and Indirect Effects (Muscle Repair) via the hepatic release of IGF-1 and activation of the mTOR pathway.
I. Introduction: The "One-Hand Clapping" Problem
To understand the ubiquity of the Ipamorelin and CJC-1295 no DAC combination in modern peptide research, one must first understand the fundamental constraints of the somatotropic axis. A common misconception in research design is viewing Growth Hormone (GH) secretion as a unidirectional "switch", that is, simply adding a stimulus will result in linear release.
However, the hypothalamus does not govern the pituitary gland solely through stimulation. It maintains homeostasis through a tightly regulated "push-pull" mechanism involving two opposing neuropeptides: Growth Hormone Releasing Hormone (GHRH) and Somatostatin (SST).
The Inhibitory Tone (The "Brake")
GHRH acts as the accelerator, binding to receptors on somatotroph cells to stimulate cAMP production and GH release. Conversely, Somatostatin acts as the physiological brake. When Somatostatin tone is high, it actively inhibits the release of GH, even in the presence of GHRH.
This creates a significant rate-limiting step for single-peptide protocols. Research indicates that administering an analog of GHRH (such as CJC-1295) during a period of high Somatostatin tone results in a blunted secretory event. The pituitary receives the signal to release, but the inhibitory "brake" prevents the exocytosis of secretory granules. This is the "one-hand clapping" problem: without addressing the inhibitory signal, the stimulatory signal is inefficient.
The Two-Pronged Solution
The rationale behind co-administering Ipamorelin and CJC-1295 is to simultaneously address both sides of this regulatory equation.
Releasing the Brake: Ipamorelin, a selective agonist of the Ghrelin/Growth Hormone Secretagogue Receptor (GHSR-1a), initiates a signaling cascade that effectively suppresses Somatostatin tone.
Pushing the Gas: With the inhibitory brake released, the pituitary becomes highly sensitized. CJC-1295 (a GHRH analog) can then bind to the GHRH receptor with maximal efficacy.
Pharmacodynamic data suggests that this combination does not merely produce an additive effect (1+1=2), but rather a synergistic one. By coordinating the "disinhibition" of Somatostatin with the "stimulation" of GHRH, this approach aims to replicate the high-amplitude pulsatile release characteristic of optimized physiological states, rather than the low-amplitude, irregular secretion often observed in isolated models.
II. The Biology of the "Pulse" (The Problem)
To understand why the Ipamorelin/CJC-1295 combination is necessary, one must first define the mechanical failure it is designed to repair. This failure is known clinically as somatopause.
Contrary to popular belief, somatopause is not caused by the pituitary gland "running out" of Growth Hormone. Histological studies on aging pituitary glands reveal that the somatotrophs (GH-producing cells) remain morphologically intact and fully stocked with secretory granules well into the seventh and eighth decades of life. The engine is not broken; the ignition signal is failing.
Research characterizing Natural Growth Hormone Pulsatility has quantified this decline. In healthy young adults, GH is secreted in 6–9 discrete pulses per 24-hour period, with the majority of total output occurring during slow-wave sleep (SWS). In aging models, while the frequency of these pulses remains relatively stable, the amplitude collapses. Data indicates that the integrated GH concentration in elderly subjects is approximately 32% to 56% of that found in young adults. This attenuation is a function of signaling dissonance between two primary neuroendocrine factors:
1. GHRH (The "Go" Signal)
Growth Hormone Releasing Hormone initiates the release process via the cAMP-dependent pathway.
Mechanism: GHRH binds to the GHRH-Receptor (a G-protein coupled receptor) on the somatotroph surface.
Signaling Cascade: This activates the Gs-alpha subunit, which stimulates adenylyl cyclase to convert ATP into cyclic AMP (cAMP).
The Result: Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates voltage-gated Calcium channels (L-type and T-type). This causes an influx of intracellular Calcium (Ca2+), triggering the exocytosis of GH-containing vesicles.
2. Somatostatin (The "Stop" Signal)
Somatostatin (SST) is the dominant inhibitory factor, and its "tone" (baseline activity) tends to increase with age.
Mechanism: SST binds to Somatostatin Receptors (primarily sst2 and sst5) on the pituitary.
Signaling Cascade: This activates the Gi-alpha subunit (inhibitory), which directly opposes GHRH by inhibiting adenylyl cyclase and reducing cAMP levels.
The Hyperpolarization Effect: Crucially, SST also activates G-protein-coupled Inwardly-rectifying Potassium channels (GIRK). This causes Potassium (K+) efflux, hyperpolarizing the cell membrane and preventing the Calcium influx necessary for release.
The Clinical Consequence: In a state of high Somatostatin tone (common in aging), even a strong GHRH signal is blunted. The GHRH steps on the gas (cAMP increase), but Somatostatin has the parking brake engaged (Hyperpolarization). This is why administering CJC-1295 alone often yields suboptimal results, it cannot overcome the hyperpolarized state induced by Somatostatin.
III. The Synergy Mechanism: 1 + 1 = 5
In pharmacological terms, the interaction between CJC-1295 (a GHRH analog) and Ipamorelin (a GH Secretagogue) is defined not as "addition," but as potentiation.
While "addition" implies that the total effect is the sum of the individual parts (A + B = C), potentiation occurs when one agent enhances the sensitivity of the target tissue to the other, resulting in an exponential output (A x B = C). This phenomenon relies on the simultaneous activation of two distinct, yet complementary, G-protein signaling pathways within the somatotroph cell.
1. The Amplifier: CJC-1295 (The cAMP Pathway)
As established, CJC-1295 mimics the action of GHRH. It binds to the GHRH receptor, activating the Gs-alpha protein subunit.
Primary Action: Stimulation of Adenylyl Cyclase (AC).
Downstream Effect: This increases intracellular concentrations of cyclic AMP (cAMP).
The Limitation: While cAMP creates the potential for a massive release event by activating Protein Kinase A (PKA), the release cannot occur if the cell membrane is hyperpolarized (electrically stabilized) by Somatostatin. The "fuel" is present, but the "spark" is weak.
2. The Trigger: Ipamorelin (The PLC Pathway)
Ipamorelin operates via a completely separate mechanism. It binds to the Growth Hormone Secretagogue Receptor 1a (GHSR-1a). Unlike the GHRH receptor, this is coupled to a Gq/11-alpha protein.
Primary Action: Activation of Phospholipase C (PLC).
Downstream Effect: PLC hydrolyzes membrane phospholipids (PIP2) into two critical second messengers: Inositol Triphosphate (IP3) and Diacylglycerol (DAG).
The "Spark": IP3 travels to the Endoplasmic Reticulum (ER) and forces the release of stored intracellular Calcium (Ca2+) reserves.
The "Cross-Talk": Why Synergy Occurs
The "1 + 1 = 5" effect is driven by the biochemical convergence of these two pathways.
Membrane Depolarization: Activation of the GHSR-1a by Ipamorelin inhibits the potassium channels (K+) that Somatostatin tries to open. This depolarizes the cell membrane, effectively neutralizing the Somatostatin "brake."
Calcium-cAMP Synergy: The intracellular Calcium flood caused by Ipamorelin (via IP3) acts as a force multiplier for the cAMP signal generated by CJC-1295. High concentrations of intracellular Ca2+ enhance the efficiency of exocytosis machinery.
Quantitative Evidence
Research comparing single-peptide administration versus co-administration consistently demonstrates this supra-additive relationship.
In landmark studies characterizing the synergy between GHRH and GHRPs (the class to which Ipamorelin belongs), data indicates that co-administration yields a Growth Hormone Area Under the Curve (AUC) response that is significantly greater than the algebraic sum of the individual responses.
Specifically, while GHRH administration alone typically elevates plasma GH to moderate physiological peaks (e.g., 10–20 ng/mL in varying models), the addition of a GHRP can amplify this peak by a factor of 3- to 5-fold. The CJC-1295/Ipamorelin approach exploits this precise mechanism: CJC-1295 loads the cell with cAMP (synthesis potential), while Ipamorelin triggers the Calcium surge (release event) and blocks Somatostatin interference.
IV. CJC-1295: The "DAC" Confusion
One of the most persistent nomenclatural errors in the peptide industry is the conflation of Modified GRF 1-29 and CJC-1295. While often sold interchangeably or labeled as "CJC-1295 No DAC," these two compounds possess vastly different pharmacokinetic profiles. To audit a research protocol effectively, one must distinguish between the pulsatile agent (Mod GRF 1-29) and the long-acting conjugate (CJC-1295 with DAC).
The Biochemistry of "DAC" (Drug Affinity Complex)
The distinction lies in a specific chemical modification developed by ConjuChem known as the Drug Affinity Complex (DAC). The 'DAC' technology works by binding to serum albumin, extending the half-life to 8 days
Modified GRF 1-29 is a tetrasubstituted analog of the first 29 amino acids of endogenous GHRH. Modifications at positions 2, 8, 15, and 27 protect it from enzymatic degradation by DPP-IV, extending its half-life from ~7 minutes (native GHRH) to approximately 30 minutes. This duration is sufficient to trigger a single, defined pulse of GH before clearing the system. True CJC-1295 takes this tetrasubstituted backbone and adds a chemical linker, Maleimidopropionic Acid (MPA), to the Lysine residue at position 13.
The "Velcro" Mechanism: Albumin Conjugation
The addition of the MPA linker fundamentally alters the peptide’s behavior in vivo. Upon injection, the reactive maleimide group forms a stable covalent bond with the free thiol group on Cysteine-34 of serum albumin.
This phenomenon is often described as a "Velcro" effect. By piggybacking onto serum albumin (a massive 67 kDa protein), the peptide bypasses renal clearance.
Glomerular Filtration: The kidneys filter out small peptides rapidly. However, the Albumin-CJC-1295 complex is too large to pass through the glomerulus.
The Result: The half-life extends from minutes to 6–8 days.
Research by Teichman et al. (2006) quantified this effect in human subjects, demonstrating that a single administration of CJC-1295 maintained elevated mean GH and IGF-1 levels for over a week.
The Safety Argument: "Pulse" vs. "Bleed"
While a week-long duration appears advantageous for convenience, it presents a significant deviation from human physiology. The somatotropic axis is evolutionarily designed to operate in pulses, not continuous waves.
1. The Phenomenon of "GH Bleed" The Teichman data revealed that while CJC-1295 preserved some pulsatility, it significantly elevated basal (trough) GH levels. This state of constant receptor agonism is clinically referred to as "GH bleed."
2. Desensitization and Insulin Resistance Continuous exposure to GH disrupts the delicate metabolic balance of the body.
Lipolysis & The Randle Cycle: Constant GH elevation drives continuous lipolysis, flooding the bloodstream with Free Fatty Acids (FFAs). According to the Randle Cycle hypothesis, high plasma FFAs competitively inhibit glucose uptake and oxidation in muscle tissue.
The Outcome: This mechanism is strongly linked to the development of insulin resistance. Unlike the pulsatile release of Mod GRF 1-29, which allows insulin sensitivity to reset between pulses, the "bleed" of DAC creates a persistent hyperglycemic pressure.
3. Water Retention Continuous activation of the mineralocorticoid pathways (often cross-activated by high IGF-1/GH states) leads to sodium retention. This manifests as significant edema (water retention), a side effect frequently reported in clinical data regarding long-acting GH secretagogues but rarely observed with pulsatile Mod GRF 1-29.
Summary: The industry preference for "No DAC" (Mod GRF 1-29) is driven by the goal of biomimicry. The objective is to amplify the natural spike, not to create an artificial plateau.
V. Ipamorelin: The "Selective" Advantage
In the chronology of Growth Hormone Secretagogue (GHS) development, Ipamorelin represents the third generation, a molecule engineered specifically to solve the "spillover" problem inherent in earlier compounds like GHRP-6 and GHRP-2.
While early secretagogues were effective at triggering GH release, they were pharmacologically "dirty." They acted as non-selective agonists, triggering a cascade of off-target hormonal events, most notably the stimulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis.
The Selectivity Breakthrough (Raun et al., 1998)
The defining characteristic of Ipamorelin, and the primary reason it has superseded GHRP-6 in modern protocols, is its high specificity for the GHS-R1a receptor without cross-reactivity in ACTH or Prolactin pathways.
This selectivity was first quantified in the seminal paper by Raun et al. (1998), titled "Ipamorelin, the first selective growth hormone secretagogue."
In comparative assays, the study demonstrated that while GHRP-6 and GHRP-2 induced significant releases of ACTH (Adrenocorticotropic Hormone) and Cortisol alongside Growth Hormone, Ipamorelin did not.
Potency: Ipamorelin displayed efficacy and potency for GH release comparable to GHRP-6 (EC50 values were nearly identical).
Specificity: Crucially, even at dosages 200-fold higher than the effective dose for GH release, Ipamorelin failed to induce any significant elevation in plasma ACTH or Cortisol levels.
The "Zero Cortisol" Significance
This lack of ACTH stimulation is critical for research applications involving recovery or anabolism.
The Cortisol Conflict: Cortisol is chemically catabolic; it mobilizes amino acids from muscle tissue to convert into glucose (gluconeogenesis).
The Protocol Failure: Using a non-selective secretagogue (like GHRP-2) creates a contradictory biological environment: the GH signal says "build," but the co-released Cortisol signal says "break down."
The Ipamorelin Advantage: By stimulating the somatotropic axis while leaving the HPA axis dormant, Ipamorelin allows for a purely anabolic signaling environment, free from the catabolic interference of corticosteroids.
The "Hunger" Myth
A common physiological side effect of the GHS class is extreme gastric motility and appetite stimulation, often described as "voracious hunger." This occurs because the GHS receptor is a homolog of the Ghrelin receptor (the "hunger hormone").
GHRP-6 is notorious for this effect due to its intense stimulation of gastric emptying and hypothalamic neuropeptide Y (NPY) neurons. However, pharmacological profiling indicates that Ipamorelin acts as a distinct agonist. While it binds to the same receptor, its downstream signaling profile differs.
Research investigating Ipamorelin for the treatment of Postoperative Ileus (Greenwood-Van Meerveld, 2012) indicated that while Ipamorelin does possess pro-kinetic properties (it moves food through the gut), its effect on the "hunger" signaling pathways is markedly attenuated compared to GHRP-6. It provides the GH pulse without the concurrent spike in varying gastric peptides that drive the uncontrollable appetite response observed in first-generation secretagogues.
VI. The Biological Payoff: What Actually Happens?
To understand the physiological impact of the Ipamorelin/CJC-1295 approach, one must analyze the downstream effects of the Growth Hormone molecule itself. In endocrinology, GH is classified as a "Dual Effector" because it operates through two distinct, yet complementary, pathways: Direct Effects (mediated by the GH receptor itself) and Indirect Effects (mediated by the production of IGF-1).
Subsection A: Fat Loss (The Direct Effect)
The "lipolytic" (fat-burning) properties of this dual GH peptide approach are driven directly by the binding of GH to receptors on adipose tissue, functioning as a nutrient partitioning agent.
The Mechanism: The "Lipid Switch" When GH binds to the transmembrane Growth Hormone Receptor (GHR) on an adipocyte (fat cell), it activates the JAK2-STAT5 signaling pathway. This initiates a two-front biochemical attack on fat storage:
Inhibition of Lipoprotein Lipase (LPL): LPL is the enzyme responsible for hydrolyzing triglycerides in the bloodstream so they can be absorbed and stored by fat cells. GH creates a transcriptional blockade of LPL, effectively "locking the door" and preventing the adipocyte from accumulating new fat.
Activation of Hormone-Sensitive Lipase (HSL): Simultaneously, GH triggers a phosphorylation cascade that activates HSL. This enzyme breaks down stored triglycerides into free fatty acids (FFAs) and glycerol, forcing the cell to release its stored energy into the bloodstream for oxidation.
Subsection B: Muscle & Recovery (The Indirect Effect)
While GH liberates energy, it is the secondary mediator, Insulin-Like Growth Factor 1 (IGF-1), that directs that energy toward tissue repair.
The Mechanism: The mTOR Cascade The surge in GH stimulates the liver (hepatic origin) and skeletal muscle (autocrine/paracrine origin) to synthesize IGF-1.
The Pathway: IGF-1 binds to the IGF-1 Receptor (IGF-1R) on the surface of muscle cells, triggering the PI3K/Akt pathway.
The Target: This signaling chain activates mTOR (mammalian target of rapamycin), the master regulator of protein synthesis.
Satellite Cell Activation: Beyond simple hypertrophy (growing existing fibers), local IGF-1 is critical for the proliferation of satellite cells (muscle stem cells). These cells donate new nuclei to damaged muscle fibers, maintaining the "myonuclear domain" required for tissue repair and growth.
Subsection C: Sleep & Neurological Function
The relationship between GHRH/GH and sleep is bidirectional. While Deep Slow-Wave Sleep (SWS) is the primary trigger for endogenous GH secretion, the signaling peptides themselves play a role in sleep architecture.
The Mechanism: GABAergic Modulation Research indicates that GHRH (and analogs like CJC-1295) acts as a sleep-promoting substance (SPS).
NREM Promotion: Intracerebroventricular administration of GHRH has been shown to increase the duration and intensity of Non-Rapid Eye Movement (NREM) sleep.
GABAergic Pathways: This effect is believed to be mediated through the modulation of GABAergic neurons in the preoptic area of the hypothalamus. By enhancing the depth of SWS, the Ipamorelin + CJC-1295 no DAC approach creates a positive feedback loop: the peptide induces deeper sleep, and deeper sleep facilitates further endogenous hormone pulsatility.
References
1. Anderson, J. LinkedIn Profile. LinkedIn https://www.linkedin.com/in/johnathonanderson/ (2024).
2. Volpi, E., Nazemi, R. & Fujita, S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 7, 405–410 (2004). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804956/
3. Chertman, L. S., Merriam, G. R. & Kargi, A. Y. Growth Hormone in Aging. Endotext (2019). https://www.ncbi.nlm.nih.gov/books/NBK279163/
4. Srikanthan, P. & Karlamangla, A. S. Muscle mass index as a predictor of longevity in older adults. American Journal of Medicine 127, 547–553 (2014). https://www.amjmed.com/article/S0002-9343(14)00138-7/fulltext
5. Velloso, C. P. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol 154, 557–568 (2008). https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/bjp.2008.153
6. Zhu, H. et al. Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults. PLoS One 12, e0185561 (2017). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185561
7. National Library of Medicine. IGF-1 (Insulin-like Growth Factor 1) Test. MedlinePlus.gov https://medlineplus.gov/lab-tests/igf-1-insulin-like-growth-factor-1-test/#:~:text=This%20test%20measures%20the%20amount,growth%20of%20bones%20and%20tissues. (2024).
8. Taaffe, D. R., Jin, I. H., Vu, T. H., Hoffman, A. R. & Marcus, R. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81, 421–425 (1996). https://academic.oup.com/jcem/article-abstract/81/1/421/2649610?redirectedFrom=fulltext&login=false
9. Welle, S., Thornton, C., Statt, M. & Mchenry, B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 81, 3239–3243 (1996). https://pubmed.ncbi.nlm.nih.gov/8784075/
10. Rudman, D. et al. Effects of Human Growth Hormone in Men over 60 Years Old. http://dx.doi.org/10.1056/NEJM199007053230101 323, 1–6 (1990). https://www.nejm.org/doi/10.1056/NEJM199007053230101?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
11. Nass, R. et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Ann Intern Med 149, 601–611 (2008).
12. Giannoulis, M. G. et al. The Effects of Growth Hormone and/or Testosterone in Healthy Elderly Men: A Randomized Controlled Trial. J Clin Endocrinol Metab 91, 477–484 (2006). https://www.acpjournals.org/doi/full/10.7326/0003-4819-149-9-200811040-00003?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
13. Blackman, M. R. et al. Growth Hormone and Sex Steroid Administration in Healthy Aged Women and Men: A Randomized Controlled Trial. JAMA 288, 2282–2292 (2002). https://jamanetwork.com/journals/jama/fullarticle/1108358
14. Brill, K. T. et al. Single and Combined Effects of Growth Hormone and Testosterone Administration on Measures of Body Composition, Physical Performance, Mood, Sexual Function, Bone Turnover, and Muscle Gene Expression in Healthy Older Men. J Clin Endocrinol Metab 87, 5649–5657 (2002). https://pubmed.ncbi.nlm.nih.gov/12466367/
15. Lange, K. H. W. et al. GH Administration Changes Myosin Heavy Chain Isoforms in Skeletal Muscle But Does Not Augment Muscle Strength or Hypertrophy, Either Alone or Combined with Resistance Exercise Training in Healthy Elderly Men. J Clin Endocrinol Metab 87, 513–523 (2002). https://pubmed.ncbi.nlm.nih.gov/11836279/
16. Yarasheski, K. E., Zachwieja, J. J., Campbell, J. A. & Bier, D. M. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. https://doi.org/10.1152/ajpendo.1995.268.2.E268 268, (1995). https://journals.physiology.org/doi/abs/10.1152/ajpendo.1995.268.2.E268?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
17. Hennebry, A. et al. IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice. Journal of Endocrinology 234, 187–200 (2017).
18. Yoshida, T. & Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020, Vol. 9, Page 1970 9, 1970 (2020).
19. Al-Samerria, S. & Radovick, S. Exploring the Therapeutic Potential of Targeting GH and IGF-1 in the Management of Obesity: Insights from the Interplay between These Hormones and Metabolism. International Journal of Molecular Sciences 2023, Vol. 24, Page 9556 24, 9556 (2023). https://joe.bioscientifica.com/view/journals/joe/234/2/JOE-17-0032.xml
20. Generali, J. A. & Cada, D. J. Recombinant Human Growth Hormone: HIV-Related Lipodystrophy. http://dx.doi.org/10.1310/hpj4905-432 49, 432–434 (2014). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062715/
21. Adrian, S. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154 (2019). https://link.springer.com/article/10.14283/jfa.2018.45
22. Kopchick, J. J., Berryman, D. E., Puri, V., Lee, K. Y. & Jorgensen, J. O. L. The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nature Reviews Endocrinology 2019 16:3 16, 135–146 (2019). https://www.nature.com/articles/s41574-019-0280-9
23. Siemensma, E. P. C. et al. Beneficial Effects of Growth Hormone Treatment on Cognition in Children with Prader-Willi Syndrome: A Randomized Controlled Trial and Longitudinal Study. J Clin Endocrinol Metab 97, 2307–2314 (2012). https://academic.oup.com/jcem/article-abstract/97/7/2307/2834113?redirectedFrom=fulltext
24. Stephen, M. D. et al. Health-related quality of life and cognitive functioning in pediatric short stature: Comparison of growth-hormone-naïve, growth-hormone-treated, and healthy samples. Eur J Pediatr 170, 351–358 (2011). https://link.springer.com/article/10.1007/s00431-010-1299-z
25. Baker, L. D. et al. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. Arch Neurol 69, 1420–1429 (2012). https://jamanetwork.com/journals/jamaneurology/fullarticle/1306261
26. Deijen, J. B., De Boer, H. & Van Der Veen, E. A. Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 23, 45–55 (1998). https://www.sciencedirect.com/science/article/abs/pii/S0306453097000929?via%3Dihub
27. Maric, N. P. et al. Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy. Journal of Endocrinological Investigation 2010 33:11 33, 770–775 (2014). https://link.springer.com/article/10.1007/BF03350340
28. Johansson, J. O. et al. Treatment of Growth Hormone-Deficient Adults with Recombinant Human Growth Hormone Increases the Concentration of Growth Hormone in the Cerebrospinal Fluid and Affects Neurotransmitters. Neuroendocrinology 61, 57–66 (1995). https://karger.com/nen/article-abstract/61/1/57/224415/Treatment-of-Growth-Hormone-Deficient-Adults-with?redirectedFrom=fulltext
29. Lai, Z. et al. Age-related reduction of human growth hormone-binding sites in the human brain. Brain Res 621, 260–266 (1993). https://pubmed.ncbi.nlm.nih.gov/8242339/
30. Pathipati, P. et al. Growth hormone and prolactin regulate human neural stem cell regenerative activity. Neuroscience 190, 409–427 (2011). https://pubmed.ncbi.nlm.nih.gov/21664953/
31. Chung, J. Y., Kim, H. J. & Kim, M. The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neurons. BMC Neurosci 16, 1–11 (2015). https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-015-0140-z
32. Siebert, D. M. & Rao, A. L. The Use and Abuse of Human Growth Hormone in Sports. https://doi.org/10.1177/1941738118782688 10, 419–426 (2018). https://journals.sagepub.com/doi/10.1177/1941738118782688
33. Longobardi, S. et al. Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study. J Clin Endocrinol Metab 85, 1505–1512 (2000). https://pubmed.ncbi.nlm.nih.gov/10770189/
34. Nelson, A. E. et al. Pharmacodynamics of Growth Hormone Abuse Biomarkers and the Influence of Gender and Testosterone: A Randomized Double-Blind Placebo-Controlled Study in Young Recreational Athletes. J Clin Endocrinol Metab 93, 2213–2222 (2008). https://pubmed.ncbi.nlm.nih.gov/18381573/
35. Doessing, S. et al. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol 588, 341–351 (2010). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821728/
36. Holt, R. I. G. & Ho, K. K. Y. The Use and Abuse of Growth Hormone in Sports. Endocr Rev 40, 1163–1185 (2019).
37. Khatri, M., Naughton, R. J., Clifford, T., Harper, L. D. & Corr, L. The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review. Amino Acids 53, 1493–1506 (2021). https://pubmed.ncbi.nlm.nih.gov/31180479/
38. Lee, J., Bridge, J. E., Clark, D. R., Stewart, C. E. & Erskine, R. M. Collagen supplementation augments changes in patellar tendon properties in female soccer players. Front Physiol 14, 1089971 (2023). https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2023.1089971/full
39. Kerkhofs, M. et al. Sleep-promoting effects of growth hormone-releasing hormone in normal men. https://doi.org/10.1152/ajpendo.1993.264.4.E594 264, (1993). https://journals.physiology.org/doi/abs/10.1152/ajpendo.1993.264.4.E594?journalCode=ajpendo
40. Perras, B., Marshall, L., Köhler, G., Born, J. & Fehm, H. L. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology 24, 743–757 (1999). https://pubmed.ncbi.nlm.nih.gov/10451909/
41. Copinschi, G. et al. Prolonged Oral Treatment with MK-677, a Novel Growth Hormone Secretagogue, Improves Sleep Quality in Man. Neuroendocrinology 66, 278–286 (1997). https://karger.com/nen/article-abstract/66/4/278/224995/Prolonged-Oral-Treatment-with-MK-677-a-Novel?redirectedFrom=fulltext
42. Kluge, M. et al. Ghrelin alone or co-administered with GHRH or CRH increases non-REM sleep and decreases REM sleep in young males. Psychoneuroendocrinology 33, 497–506 (2008). https://www.sciencedirect.com/science/article/abs/pii/S0306453008000292
43. Edmondson, S. R., Thumiger, S. P., Werther, G. A. & Wraight, C. J. Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems. Endocr Rev 24, 737–764 (2003). https://academic.oup.com/edrv/article-abstract/24/6/737/2567213?redirectedFrom=fulltext&login=false
44. Recombinant Human Growth Hormone Accelerates Wound Healing i... : Annals of Surgery. https://journals.lww.com/annalsofsurgery/abstract/1994/07000/recombinant_human_growth_hormone_accelerates_wound.4.aspx.
45. Jørgensen, P. H., Bang, C., Andreassen, T. T., Flyvbjerg, A. & Ørskov, H. Dose-response study of the effect of growth hormone on mechanical properties of skin graft wounds. Journal of Surgical Research 58, 295–301 (1995). https://www.journalofsurgicalresearch.com/article/S0022-4804(85)71046-3/abstract
46. The Effect of Topically Applied Recombinant Human Growth Hormone on Wound Healing in Pigs. Wounds 21, (2009). https://pubmed.ncbi.nlm.nih.gov/25903440/
47. Cristóbal, L. et al. Local Growth Hormone Therapy for Pressure Ulcer Healing on a Human Skin Mouse Model. Int J Mol Sci 20, (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747216/
48. Dioufa, N. et al. Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci U S A 107, 18611–18615 (2010). https://www.pnas.org/doi/full/10.1073/pnas.1013942107
49. Krantz, E., Trimpou, P. & Landin-Wilhelmsen, K. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study. J Clin Endocrinol Metab 100, 3251–3259 (2015). https://pubmed.ncbi.nlm.nih.gov/26312576/
50. Landin-Wilhelmsen, K., Nilsson, A., Bosaeus, I. & Bengtsson, B. Å. Growth Hormone Increases Bone Mineral Content in Postmenopausal Osteoporosis: A Randomized Placebo-Controlled Trial. Journal of Bone and Mineral Research 18, 393–405 (2003). https://academic.oup.com/jbmr/article-abstract/18/3/393/7592512?redirectedFrom=fulltext&login=false
51. Gillberg, P., Mallmin, H., Petrén-Mallmin, M., Ljunghall, S. & Nilsson, A. G. Two Years of Treatment with Recombinant Human Growth Hormone Increases Bone Mineral Density in Men with Idiopathic Osteoporosis. J Clin Endocrinol Metab 87, 4900–4906 (2002). https://academic.oup.com/jcem/article-abstract/87/11/4900/2823079?redirectedFrom=fulltext
52. Van Der Sluis, I. M. et al. Long-Term Effects of Growth Hormone Therapy on Bone Mineral Density, Body Composition, and Serum Lipid Levels in Growth Hormone Deficient Children: A 6-Year Follow-Up Study. Horm Res 58, 207–214 (2002). https://pubmed.ncbi.nlm.nih.gov/12401939/
53. Xue, P., Wang, Y., Yang, J. & Li, Y. Effects of growth hormone replacement therapy on bone mineral density in growth hormone deficient adults: A meta-analysis. Int J Endocrinol 2013, (2013). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652209/
54. Olney, R. C. Regulation of bone mass by growth hormone. Med Pediatr Oncol 41, 228–234 (2003). https://onlinelibrary.wiley.com/doi/10.1002/mpo.10342
55. Giustina, A., Mazziotti, G. & Canalis, E. Growth Hormone, Insulin-Like Growth Factors, and the Skeleton. Endocr Rev 29, 535 (2008). https://pubmed.ncbi.nlm.nih.gov/18436706/
56. Genth-Zotz, S. et al. Recombinant Growth Hormone Therapy in Patients With Ischemic Cardiomyopathy. Circulation 99, 18–21 (1999). https://www.ahajournals.org/doi/10.1161/01.cir.99.1.18?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
57. Osterziel, K. J. et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233–1237 (1998). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)11329-0/abstract
58. Erafino, S. et al. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy. https://doi.org/10.1056/NEJM199603283341301 334, 809–814 (1996). https://www.nejm.org/doi/full/10.1056/NEJM199603283341301
59. Amirpour, A. et al. The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial. Cardiovasc Ther 2021, (2021). https://onlinelibrary.wiley.com/doi/10.1155/2021/2680107
60. Colao, A. et al. Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency. J Clin Endocrinol Metab 93, 3416–3424 (2008). https://academic.oup.com/jcem/article-abstract/93/9/3416/2596763?redirectedFrom=fulltext
61. Maison, P. & Chanson, P. Cardiac Effects of Growth Hormone in Adults With Growth Hormone Deficiency. Circulation 108, 2648–2652 (2003). https://www.ahajournals.org/doi/10.1161/01.CIR.0000100720.01867.1D?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
62. Caicedo, D., Díaz, O., Devesa, P. & Devesa, J. Growth Hormone (GH) and Cardiovascular System. International Journal of Molecular Sciences 2018, Vol. 19, Page 290 19, 290 (2018). https://www.mdpi.com/1422-0067/19/1/290
63. Caicedo, D., Devesa, P., Alvarez, C. V. & Devesa, J. Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial. Cells 2020, Vol. 9, Page 807 9, 807 (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226428/
64. Thum, T. et al. Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1. Circ Res 100, 434–443 (2007). https://www.ahajournals.org/doi/10.1161/01.RES.0000257912.78915.af
65. Falutz, J. et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22, 1719–1728 (2008). https://journals.lww.com/aidsonline/fulltext/2008/09120/long_term_safety_and_effects_of_tesamorelin,_a.6.aspx
66. Stanley, T. L. et al. Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin. Clinical Infectious Diseases 54, 1642–1651 (2012). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348954/
67. Falutz, J. et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. J Clin Endocrinol Metab 95, 4291–4304 (2010). https://pubmed.ncbi.nlm.nih.gov/20554713/
68. Broglio, F. et al. Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. Eur J Endocrinol 143, 419–425 (2000). https://academic.oup.com/ejendo/article-lookup/doi/10.1530/eje.0.1430419
69. Engström, G., Lindström, P. & Sävendahl, L. Lack of Evidence for Acute Effects of Growth Hormone-Releasing Hormone on Serum Insulin and Glucose Levels in Normal and Hypophysectomized Rats. Horm Res 41, 21–26 (1994). https://pubmed.ncbi.nlm.nih.gov/8013938/
70. Falutz, J. et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. J Clin Endocrinol Metab 95, 4291–4304 (2010). https://pubmed.ncbi.nlm.nih.gov/20554713/
